Broadwood Partners, L.P., a director and 10% owner of Lineage Cell Therapeutics, Inc. (NYSE:LCTX), filed a Form 4 on November 19, 2026, disclosing the purchase of 1,000,000 common shares on November 17, 2026.

Key Highlights

  • Purchase transaction: Broadwood Partners acquired 1,000,000 common shares on November 17, 2026, at a price of $0.7707 per share (transaction code P).
  • Resulting direct ownership: Following the transaction, Broadwood Partners directly holds 50,560,992 common shares.
  • Personal holdings: Neal C. Bradsher separately holds 87,628 common shares in his personal capacity.
  • Warrants held: Broadwood Partners also holds 7,894,737 Common Warrants exercisable at $0.91 per share, expiring no later than May 21, 2028, subject to an earlier expiration condition tied to OpRegen (RG6501) clinical trial disclosure.
  • Three reporting persons: The filing was made jointly by Broadwood Partners, L.P., Broadwood Capital, Inc. (as General Partner), and Neal C. Bradsher (as President of Broadwood Capital, Inc.).

Broadwood Partners Increases Lineage Cell Therapeutics Stake in November 2026

According to the Form 4 filed with the SEC on November 19, 2026, Broadwood Partners, L.P. reported a purchase of 1,000,000 common shares of Lineage Cell Therapeutics, Inc. on November 17, 2026, at $0.7707 per share. The filing identifies Broadwood Partners as both a director and a 10% owner of the issuer. Following the reported transaction, the filing states that Broadwood Partners directly holds 50,560,992 common shares.

The filing was made jointly by three reporting persons: Broadwood Partners, L.P.; Broadwood Capital, Inc., the General Partner of Broadwood Partners; and Neal C. Bradsher, President of Broadwood Capital, Inc. The filing notes that the reported securities are directly owned by Broadwood Partners and "may be deemed beneficially owned" by Broadwood Capital, Inc. and Neal C. Bradsher. Each reporting person disclaims beneficial ownership except to the extent of their own pecuniary interest, and the report "shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16."

In addition to common shares, the filing discloses that Broadwood Partners holds 7,894,737 Common Warrants with an exercise price of $0.91 per share, which are described as currently exercisable. According to the filing, these warrants expire on the earlier of May 21, 2028, or the 90th day following public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial that includes a control or comparator arm. Neal C. Bradsher also holds 87,628 common shares in his personal capacity, as noted in the filing.

What Was Disclosed

Broadwood Partners, L.P. reported a purchase of 1,000,000 Lineage Cell Therapeutics common shares at $0.7707 on November 17, 2026, bringing its direct holdings to 50,560,992 shares, alongside 7,894,737 outstanding Common Warrants exercisable at $0.91.